Sphaera Pharma Research And Development Private Limited - Due diligence report

A 360° intelligence report on Sphaerapharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2008-11-28 New Delhi, Delhi Active Unlisted Active Compliant
Share
SP Sphaera Pharma Research And Development Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sphaerapharma — 360° Intelligence Report

Generated from MCA filings & public records
65/100
Trust Score
Moderate

Sphaerapharma is assessed as Moderate with a Trust Score of 65/100. Sphaerapharma is an active private limited indian non-government company incorporated in 2008, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Sphaera Pharma Research And Development Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
65/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 1 satisfied (1.19 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Biotechnology Industry Research Assistance Council1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
ABHINAV DHANDIA 01234567 Director 01/04/2018 6 yrs Approved
ASHISH DUGAR 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 40
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Operating for 17+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment47/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view42/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
26 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
25 Sep 2023
Director ceased
ASHISH DUGAR
31 Mar 2023
Share transfer (FY 2023)
5000.00000000 shares to ASHISH DUGAR
02 Dec 2022
Director appointed
ASHISH DUGAR (Director)
30 Oct 2021
Director ceased
SOMDUTTA SEN
11 Jun 2021
Charge satisfied
Biotechnology Industry Research Assistance Council
31 Mar 2019
Share transfer (FY 2019)
5000.00000000 shares to Jugal Bhatia
28 Sep 2018
Director ceased
JUGAL AJIT BHATIA
06 Jun 2018
Director ceased
CHANDAN KUMAR
01 Jan 2015
Director ceased
NEHA JAI KRISHAN GROVER
30 Sep 2013
Director ceased
ABHINAV DHANDIA
22 Feb 2013
Director ceased
KRISHNAMOORTHY NARAYANASAMY
08 Jan 2013
Director appointed
ABHINAV DHANDIA (Director)
24 Sep 2012
Director ceased
BHUWAN KUMAR CHATURVEDI
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Intech Energy Systems U35106PN2005PTC020761 Pune, Maharashtra, India
Aapke Dwar Technology Private Limited U74999JH2020PTC014593 Ranchi, Jharkhand, India
Iit Palakkad Technology Ihub Foundation U73100KL2020NPL065107 Palakkad, Kerala, India
Nopel Technologies Private Limited U72100TG2016PTC112566 Hyderabad, Telangana, India
Dverse Technologies Private Limited U74999TN2021PTC146175 Chennai, Tamil Nadu, India
Natnov Bioscience Private Limited U24290OR2021PTC038366 Soro, Orissa, India
Arth Platform Technology Private Limited U73200HR2022PTC101303 Palam Road, Haryana, India
Pnb Vesper Life Science U73100KL2011PTC028397 Cochin, Kerala, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sphaerapharma before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sphaerapharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 60/100, margin trends, ownership structure and peer set for Sphaerapharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 65/100, distress signals and MSME payment-delay disclosures - know whether Sphaerapharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sphaerapharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sphaerapharma an active company?

Sphaerapharma has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Sphaerapharma financially healthy?

Sphaerapharma has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Sphaerapharma?

Its overall Trust Score is 65/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sphaerapharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Sphaerapharma have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Sphaerapharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Sphaerapharma?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.